clinical trial · NCT07744802
Evaluate the Effect of Vimseltinib on P-glycoprotein (P-gp) Inhibition in Healthy Male Participants
Deciphera Pharmaceuticals, LLC·phase1·not yet recruiting·n = 20
Healthy Male ParticipantsVimseltinibDabigatran
brief summary
The main purpose of this study is to determine the effect of vimseltinib on pharmacokinetics of P-glycoprotein (P-gp) substrate (dabigatran) in healthy male participants. This study will last approximately 21 days.
started
Aug 1, 2026
primary completion
Nov 1, 2026
completion
Dec 1, 2027
last updated
Aug 4, 2026
official title
A Phase 1, Open-label, Fixed-sequence Study to Evaluate the Effect of Vimseltinib on P-glycoprotein (P-gp) Inhibition in Healthy Male Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol